Vol 8, No 4 (2023)
Letter to the Editor
Published online: 2023-10-27

open access

Page views 385
Article views/downloads 205
Get Citation

Connect on Social Media

Connect on Social Media

The functioning in chronic illness –— a key determinant of treatment efficacy in patients with metabolic syndrome

Aldona Kubica1
Medical Research Journal 2023;8(4):326-327.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Dobrowolski P, Prejbisz A, Kuryłowicz A, et al. Metabolic syndrome — a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons. Arch Med Sci. 2022; 18(5): 1133–1156.
  2. Kubica J, Kubica A, Grąbczewska Z, et al. Efficacy of double vs. standard empagliflozin dose for METabolic syndromE tReatment (DEMETER — SIRIO 11) study. Rationale and protocol of the study. Med Res J. 2023; 8(3): 171–178.
  3. Pawłuszewicz P, Gołaszewski P, Głuszyńska P, et al. What does the volume of stomach resected during laparoscopic sleeve gastrectomy depend on and what impact does it have on postoperative results? Med Res J. 2023; 8(3): 208–215.
  4. Giordano U, Kobiałka J, Pilch J. Semaglutide as a chance for obesity treatment. Med Res J. 2023; 8(3): 262–264.
  5. Umińska JM. Multiple new therapeutic options for the treatment of obesity. Med Res J. 2023; 8(3): 265–266.
  6. Moczulska B, Leśniewska S, Nowek P, et al. The frequency of hypertension in patients with pathological obesity. Med Res J. 2023; 8(1): 29–33.
  7. Kubica A, Kubica J. Functioning in chronic disease — a key factor determining adherence to heart failure treatment. Med Res J. 2022; 7(4): 277–279.
  8. Michalski P, Kasprzak M, Kosobucka A, et al. Sociodemographic and clinical determinants of the functioning of patients with coronary artery disease. Med Res J. 2021; 6(1): 21–27.
  9. Kubica A, Pietrzykowski Ł, Michalski P, et al. The occurrence of cardiovascular risk factors and functioning in chronic illness in the Polish population of EUROASPIRE V. Cardiol J. 2022 [Epub ahead of print].
  10. Buszko K, Pietrzykowski Ł, Michalski P, et al. Validation of the functioning in Chronic Illness Scale (FCIS). Med Res J. 2018; 3(2): 63–69.
  11. Kubica A, Michalski P, Kasprzak M, et al. Functioning of patients with post-COVID syndrome — preliminary data. Med Res J. 2021; 6(3): 224–229.
  12. Kubica A, Adamski P, Bączkowska A, et al. The rationale for Multilevel Educational and Motivational Intervention in Patients after Myocardial Infarction (MEDMOTION) project is to support multicentre randomized clinical trial Evaluating Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome (ELECTRA – SIRIO 2). Med Res J. 2020; 5(4): 244–249.
  13. Fulton S, Décarie-Spain L, Fioramonti X, et al. The menace of obesity to depression and anxiety prevalence. Trends Endocrinol Metab. 2022; 33(1): 18–35.
  14. Kolotkin RL, Meter K, Williams GR. Quality of life and obesity. Obes Rev. 2001; 2(4): 219–229.
  15. Kubica A. Self-reported questionnaires for a comprehensive assessment of patients after acute coronary syndrome. Med Res J. 2019; 4(2): 106–109.
  16. Kubica A, Bączkowska A. Uzasadnienie interwencji motywacyjnych jako kluczowego elementu projektu wielopoziomowej edukacji i motywacji u pacjentów z zawałem serca (MEDMOTION). Folia Cardiologica. 2020; 15(1): 6–10.
  17. Kosobucka A, Michalski P, Pietrzykowski Ł, et al. The impact of readiness to discharge from hospital on adherence to treatment in patients after myocardial infarction. Cardiol J. 2022; 29(4): 582–590.
  18. Kubica A, Kosobucka A, Fabiszak T, et al. Assessment of adherence to medication in patients after myocardial infarction treated with percutaneous coronary intervention. Is there a place for newself-reported questionnaires? Curr Med Res Opin. 2019; 35(2): 341–349.
  19. Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Curr Med Res Opin. 2016; 32(8): 1441–1451.
  20. Kubica A. Adherence to medication in elderly patients. Med Res J. 2023; 1(8): 93–94.
  21. Kubica A, Gruchała M, Jaguszewski M, et al. Adherence to treatment — a pivotal issue in long-term treatment of patients with cardiovascular diseases. An expert standpoint. Med Res J. 2018; 2(4): 123–127.
  22. Kubica A, Pietrzykowski Ł. The therapeutic plan implementation in patients discharged from the hospital after myocardial infarction. Med Res J. 2021; 6(2): 79–82.
  23. Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–58.
  24. Kubica A, Kasprzak M, Obońska K, et al. Impact of health education on adherence to clopidogrel and clinical effectiveness of antiplatelet treatment in patients after myocardial infarction. Med Res J. 2016; 3(4): 154–159.
  25. Buszko K, Obońska K, Michalski P, et al. The Adherence Scale in Chronic Diseases (ASCD). The power of knowledge: the key to successful patient — health care provider cooperation. Med Res J. 2016; 1(1): 37–42.
  26. Ratajczak J, Kubica A, Michalski P, et al. Determinants of lipid parameters in patients without diagnosed cardiovascular disease-results of the polish arm of the EUROASPIRE v survey. J Clin Med. 2023; 12(7).
  27. Pietrzykowski Ł, Kasprzak M, Michalski P, et al. Therapy discontinuation after myocardial infarction. J Clin Med. 2020; 9(12).